ABOUT US

News

DecisionView Executive, Dr. Cosimo Spera, to speak at upcoming DIA Conference
READ MORE or (download pdf)

DecisionView Appoints Life Sciences Software Expert, Gonzalo Castro, to Vice President of Product Marketing
READ MORE or (download pdf)

DecisionView Appoints Technology Industry Veteran, Rene Pharisien, to Vice President of Worldwide Sales
READ MORE or (download pdf)

DecisionView Announces $7 Million in Series C Investment
READ MORE or (download pdf)

DecisionView Launches StudyOptimizerTM 3.5 for Improved Clinical Trial Performance
READ MORE or (download pdf)

DecisionView Signs Multi-Year Agreement with GlaxoSmithKline
READ MORE or (download pdf)

DecisionView Named Life Sciences "Cool Vendor" by Leading Analyst Firm
READ MORE or (download pdf)

 

DecisionView Executive, Dr. Cosimo Spera, to speak at upcoming DIA Conference

Session focuses on Future Advancements in Models and Algorithms for the Optimization of Clinical Trial Recruitment: Using Science to Deliver Superior Business Results

SAN FRANCISCO – May 29, 2008 – DecisionView Inc., the leading provider of software solutions designed to improve time to market and reduce clinical trial costs for life sciences companies, confirmed that Dr. Cosimo Spera will be delivering a session at the Drug Information Association annual event from 10:30am - 12:00pm June 25, 2008.

For more than 20 years, academic researchers and practitioners have studied patient recruitment in clinical trials. While a variety of models and algorithms have been presented and discussed at a theoretical level, real world implementations have lacked success mostly because of the complexity of the proposed models and algorithms and the difficulty in gathering the data required at the right time. Dr. Cosimo Spera, DecisionView, Dr. Valerii V Fedorov, and Dr. Vladimir V. Anisimov, both with GlaxoSmithKline Pharmaceuticals will cover how to overcome these challenges.

 

DecisionView Appoints Life Sciences Software Expert, Gonzalo Castro, to Vice President of Product Marketing

The Leading Provider of Business Performance Optimization Applications in Life Sciences Strengthens Product Management Team

SAN FRANCISCO – January 29, 2008 – DecisionView Inc., the leading provider of software solutions designed to improve time to market and reduce clinical trial costs for life sciences companies, today announced the appointment of Gonzalo Castro as Vice President, Product Marketing and a member of the company’s management team.

With over 10 years of industry experience, Mr. Castro is a seasoned product marketing leader who has an impressive track record in developing and commercializing successful and market leading software products for the Life Sciences industry. “We are delighted to welcome Gonzalo to the DecisionView management team,” said Steve Andrade, CEO of DecisionView. “His expertise in the Life Sciences industry, coupled with his software application development and product marketing experience, makes him a strategic addition to our growing company.”

Mr. Castro joins DecisionView from Oracle Corporation, where he was Director of Life Sciences Product Strategy. Prior to Oracle, he worked at Siebel Systems in a number of roles within the Life Sciences Product Marketing group, successfully conceiving, developing, and launching applications that are used by some of the largest global pharmaceutical companies. In addition to his software career, Mr. Castro served as an Operations Research Consultant at ZS Associates where he applied advanced modeling and optimization algorithms to enhance sales and marketing strategies, generating new revenue streams for the company. Mr. Castro holds an MS in Industrial Engineering from Purdue University and an MBA from the Wharton School of Business.

“DecisionView is an exciting software company that is focused on solving significant clinical trial performance challenges using innovative analytical and predictive modeling approaches,” said Gonzalo Castro. “The market is ready for an application solution that improves the speed of clinical trials by optimizing the clinical trial enrollment process. The recent enhancements to StudyOptimizer 3.5.3, released this week, are a proof point to the company’s ongoing commitment to develop innovative solutions that deliver business value to the life sciences industry,” Castro continued.

 

DecisionView Appoints Technology Industry Veteran, Rene Pharisien, to Vice President of Worldwide Sales

The Leading Provider of Business Performance Optimization Applications in Life Sciences Strengthens Executive Management Team

SAN FRANCISCO – December 11, 2007 – DecisionView Inc., the leading provider of software solutions designed to improve time to market and reduce clinical trial costs for life sciences companies, today announced the appointment of Rene Pharisien as Vice President of Worldwide Sales and a member of the company’s executive management team.

With over 25 years of sales and marketing experience in the high tech industry, Mr. Pharisien has developed a strong track record for driving significant revenue growth, cultivating strong customer relationships and developing successful strategic business partnerships. “We are pleased to welcome Rene to DecisionView and the executive management team. His experience in building and leading high performance sales organizations in high growth technology companies will be a tremendous asset to the company,” said Steve Andrade, CEO of DecisionView.

Rene began his technology sales career with Prime Computer where he quickly rose through the ranks becoming one of the youngest managers in the company’s history. He subsequently held key posts at several leading technology companies including Siebel Systems, Sequent and 3Com. Most recently Mr. Pharisien was Senior Vice President of Worldwide Sales at Kintera, a “Software-as-a-Service” company and previously held executive management positions with Niku as Vice President of Marketing and at Epiphany where he was Western Area Vice President of Sales.

“I am delighted to join DecisionView and look forward to executing on the company’s compelling vision and strategy. The clinical trial process is mission critical for life sciences companies and managing that process effectively is a key component in reducing costs and improving effectiveness in the healthcare industry,” said Rene Pharisien. “StudyOptimizerTM is a revolutionary software solution that is at the nexus of solving one of the biggest challenges faced by pharmaceutical and biotechnology companies—bringing new therapies to market faster and more cost effectively,” Pharisien continued.

 

DecisionView Announces $7 Million in Series C Investment

The Leading Provider of Business Performance Optimization Applications in Life Sciences Secures Funding for Growth

SAN FRANCISCO — July 30, 2007 – DecisionView, Inc., the leading provider of business performance optimization applications for the Life Sciences industry, today announced the close of a $7 million Series C round of funding led by new investor, firstVentury, as well as existing investors Partech International and Granite Ventures.

"We are delighted to be working with firstVentury. Their experience with convergent technologies in Life Sciences and relationships with European companies makes them a logical partner for DecisionView," said Steve Andrade, CEO of DecisionView. "FirstVentury's participation validates our growing leadership in delivering innovative clinical performance optimization solutions that deliver tangible business results."

In addition to the funding, David Hartford, Managing Director, firstVentury, will be joining DecisionView's Board of Directors. "We are delighted to welcome David to our Board. His experience in the IT and Life Sciences technology domains will further complement the strength and contributions of our existing board members," continued Andrade.

"DecisionView epitomizes the convergence of IT and life science which firstVentury sees as an absolute necessity in bringing affordable new treatments to market rapidly," said David Hartford, managing director, firstVentury. "We are very pleased to be part of DecisionView's move to radically improve the clinical trials process."

The funding will be used to scale its commercial growth capabilities and expand DecisionView's suite of clinical performance optimization applications, including the company's innovative clinical recruitment platform, StudyOptimizerTM. As the industry's first business performance optimization application for clinical trials, StudyOptimizer automates the recruitment process with integrated predictive modeling, simulation, planning, and rich visualization capabilities. The company was also recently named in the list of "Cool Vendors" in the "Cool Vendors in Life Sciences, 2007" report by Gartner, Inc.

"DecisionView has made great strides in developing top-tier solutions to meet the demanding needs of the Life Sciences industry," said Tom McKinley, managing partner and co-founder, Partech International. "The company and its leading-edge technology are well-poised for significant growth."

"DecisionView has developed a terrific solution for life sciences companies, and this financing will allow the company to expand its reach in the market, as well as continue to innovate," said Granite Ventures managing director Chris Hollenbeck.

 

DecisionView Launches StudyOptimizerTM 3.5 for Improved Clinical Trial Performance

StudyOptimizer 3.5 Enhances Clinical Recruitment Performance & Delivers Measurable Business Results

SAN FRANCISCO – April 30, 2007 – DecisionView Inc., the leading provider of business performance optimization software for the life sciences industry, announced today the immediate availability of StudyOptimizer 3.5 – the industry’s first business performance optimization application for clinical trials.

Designed for pharmaceutical, biotech, CRO, medical technology companies and academic research institutions, StudyOptimizer 3.5 automates the clinical recruitment process with integrated predictive modeling, analytics, simulation and rich visualization capabilities resulting in shorter cycle times, reduced recruitment costs and improved clinical operational efficiencies.

“Delays in recruitment are a leading cause of overall clinical trial delays and escalating clinical trial costs. StudyOptimizer 3.5 provides life science companies with a comprehensive application for improving the mission critical recruitment process and achieving tangible business results,” said Steve Andrade, CEO, DecisionView.

The new version delivers dynamic recruitment planning to include recruitment rate variables such as seasonality for developing robust clinical recruitment plans; advanced simulation modeling and predictive analytics that enable clinical study managers to model course corrections and alternative recruitment strategies; and rich interactive visualizations, including performance alerts and dashboards at the study, country and site level. In addition, StudyOptimizer 3.5 further enhances automated data aggregation from disparate financial and clinical systems such as CTMS and EDC, driving improvements in clinical team productivity.

“Today’s studies must reach a global patient pool and succeed in meeting their enrollment targets. By enabling consistent planning, dynamic performance forecasts and helpful visuals of enrollment progress, DecisionView’s StudyOptimizer can help study management teams succeed in efficient and effective enrollment across multiple countries,” said Jane W. Schafer, Executive Director, Global Study Planning & Technical Services, Amgen Inc.

 

DecisionView Signs Multi-Year Agreement with GlaxoSmithKline

SAN FRANCISCO – March 19, 2007 – DecisionView Inc., the leading provider of business performance optimization solutions to the life sciences industry, announced today that the company has signed a multi-year agreement with GlaxoSmithKline (GSK) to standardize on DecisionView’s StudyManager application for optimizing clinical recruitment performance. StudyManager is the industry’s first performance optimization solution for clinical trials.

“The number one issue impacting overall clinical trial cost is study delays caused by inadequate recruitment performance; specifically, poor recruitment planning, progress monitoring and execution” said Alex Lancksweert, director of Performance Metrics & Benchmarking in GSK’s Clinical Operations organization. GSK will globally deploy StudyManager across all Phase I-IV studies.

DecisionView’s StudyManager 3.2 application is used by clinical teams to optimize clinical recruitment performance in order to reduce recruitment costs and cycle times by automating planning, progress monitoring, predictive modeling and simulation capabilities within the clinical recruitment process.

“Improved visibility to current and predictive information, and enhanced enterprise agility to execute timely course corrections are critical competitive advantages to pharmaceutical companies and their clinical development performance. We look forward to working with GSK,” said Steve Andrade, CEO, DecisionView.

 

DecisionView Named Life Sciences "Cool Vendor" by Leading Analyst Firm

Vendors Selected for Gartner’s “Cool Vendor Report” are Innovative, Impactful and Intriguing.

SAN FRANCISCO, March 15, 2007 – DecisionView today announced that the company has been selected as one of the Life Science industry’s “Cool Vendors in Life Sciences, 2007” report by Gartner, Inc.

In the highly competitive life sciences market, where new product development and commercialization are key differentiators, DecisionView's StudyOptimizer application is used by pharmaceutical companies to optimize clinical recruitment performance. Through its unique approach of converging predictive modeling, simulation, visualization and dynamic planning capabilities in an automated clinical business process, StudyOptimizer enables life sciences companies to realize tangible business outcomes. “We are delighted and honored by Gartner’s designation as a Cool Vendor. We believe recognition in the Cool Vendors Report is strong validation of the business value that can be achieved by life sciences companies who adopt DecisionView’s business performance optimization solution,” said Steve Andrade, CEO, DecisionView.

About Gartner's Cool Vendors Selection Process
Gartner's listing does not constitute an exhaustive list of vendors in any given technology area, but rather is designed to highlight interesting, new and innovative vendors, products and services. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness of a particular purpose.

Gartner defines a cool vendor as a company that offers technologies or solutions that are: Innovative, enable users to do things they couldn't do before; Impactful, have, or will have, business impact (not just technology for the sake of technology); Intriguing, have caught Gartner's interest or curiosity in approximately the past six months.

 

 

Related Terms:
clinical studies, company info, employment